Blood component support in acquired coagulopathic conditions: Is there a method to the madness?

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Pandit, Trailokya Nath ^a   Sarode, Ravindra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; CLOPIDOGREL; CYTOCHROME P450; DABIGATRAN ETEXILATE; FRESH FROZEN PLASMA; HEPARIN; PHYTOMENADIONE; PRASUGREL; PROFLNINE; PROTAMINE; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; THROMBOPOIETIN; TICAGRELOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

BLOOD CLOTTING DISORDER; BLOOD COMPONENT; BLOOD GROUP TYPING; BRAIN HEMORRHAGE; CHRONIC LIVER DISEASE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; HEMOSTASIS; HUMAN; INJURY; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; BLOOD COMPONENT TRANSFUSION; CHRONIC DISEASE; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; HUMANS; LIVER DISEASES; PLATELET AGGREGATION INHIBITORS; WOUNDS AND INJURIES;

EID: 84859944372     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23179     Document Type: Review

References (86)

1. Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49: 1171-1177.
2. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: Statement of a consensus panel. Transfusion 2004; 44: 1774-1789.
3. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012; 52: 160-165.
4. Downes KA, Wilson E, Yomtovian R, et al. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion 2001; 41: 570.
5. Scott EA, Puca KE, Pietz BC, et al. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007; 47: 120-125.
6. Jacobs MR, Smith D, Heaton WA, et al. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011; 51: 2573-2582.
7. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S.
8. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: 7S-47S.
9. Sarode R, Rawal A, Lee R, et al. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol 2006; 132: 604-607.
10. Hildebrandt EF, Suttie JW. Mechanism of coumarin action: Sensitivity of vitamin K metabolizing enzymes of normal and warfarin-resistant rat liver. Biochemistry 1982; 21: 2406-2411.
11. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993; 92: 2131-2140.
12. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
13. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
14. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135: 393-400.
15. Sarode R, Matevosyan K, Bhagat R, et al. Rapid warfarin reversal: A 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg 2012; 116: 491-497.
16. Wintzen AR, de Jonge H, Loeliger EA, et al. The risk of intracerebral hemorrhage during oral anticoagulant treatment: A population study. Ann Neurol 1984; 16: 553-558.
17. Mathiesen T, Benediktsdottir K, Johnsson H, et al. Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand 1995; 91: 208-214.
18. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137: 251-254.
19. Burbury KL, Milner A, Snooks B, et al. Short-term warfarin reversal for elective surgery--using low-dose intravenous vitamin K: Safe, reliable and convenient*. Br J Haematol 2011; 154: 626-634.
20. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 117: 6091-6099.
21. Beshay JE, Morgan H, Madden C, et al. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. J Neurosurg 2010; 112: 307-318.
22. Protamine Sulphate Injection, USP [package insert]. Schaumburg, IL: APP Pharmaceuticals, LLC; 2008.
23. van Veen JJ, Maclean RM, Hampton KK, et al. Protamine reversal of low molecular weight heparin: Clinically effective? Blood Coagul Fibrinolysis Int J Haemost Thromb 2011; 22: 565-570.
24. Aalbers J, Bryer A, Klug E. FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation. Cardiovasc J Afr 2010; 21: 341.
25. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
26. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb/Hemost J Int Acad Clin Appl Thromb/Hemost 2009; 15 Suppl 1: 9S-16S.
27. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
28. Mismetti P, Laporte S. Rivaroxaban: Clinical pharmacology. Ann Fr Anesth Reanim 2008; 27 Suppl 3: S16-S21.
29. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891.
30. Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: Review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Medical Toxicol J Am Coll Med Toxicol 2011; 7: 281-287.
31. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
32. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice: Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis 2010; 25: 83-177.
33. van Ryn J, Schurer J, Kink-Eiband M, et al. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood (ASH Annual Meeting Abstracts) 2011; 118: abstract 2316.
34. Sarode R. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect? Transfusion 2011 Aug 19. DOI:10.1111/j.1537-2995. [Epub ahead of print].
35. Tuman KJ, McCarthy RJ, O'Connor CJ, et al. Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery. Anesth Analg 1996; 83: 1178-1184.
36. Lecompte T, Hardy JF. Antiplatelet agents and perioperative bleeding. Can J Anaesth 2006; 53: S103-S112.
37. Bhatt DL. Intensifying platelet inhibition - navigating between Scylla and Charybdis. New Engl J Med 2007; 357: 2078-2081.
38. Plavix® [Clopidogrel bisulfate] [package insert]. Bridgewater, NJ: Brisol-Myers Squibb/Sanofi Phar.; 2011.
39. Effient® [prasugrel] tablets [package insert]. Indianapolis, IN: Daiichi Sankyo, Inc. and Lilly USA, LLC.; 2011.
40. Brilinta™ [ticagrelor] tablets, [package insert]. Wilmington, DE: AstraZeneaca LP; 2011.
41. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2009; 361: 1045-1057.
42. Leong JY, Baker RA, Shah PJ, et al. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005; 80: 928-933.
43. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001; 29: 2271-2275.
44. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: Evidence and clinical consequences. Blood 2010; 116: 878-885.
45. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. New Engl J Med 2011; 365: 147-156.
46. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
47. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-558.
48. Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: Causes and consequences. J Thromb Haemost 2011; 9: 1713-1723.
49. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-393.
50. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49: 1017-1044.
51. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology 2008; 47: 1604-1614.
52. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroenterology 2004; 127: 1123-1130.
53. Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-979.
54. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
55. Holland L, Sarode R. Should plasma be transfused prophylactically before invasive procedures? Curr Opin Hematol 2006; 13: 447-451.
56. Matevosyan K, Madden C, Barnett SL, et al. Coagulation factor levels in neurosurgical patients with mild prolongation of prothrombin time: Effect on plasma transfusion therapy. J Neurosurg 2011; 114: 3-7.
57. Aster RH. Pooling of platelets in the spleen: Role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966; 45: 645-657.
58. Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: Distribution of sialic acid on the constituent chains. Blood 1983; 61: 1196-1202.
59. Francis JL, Armstrong DJ. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease. Haemostasis 1982; 11: 215-222.
60. Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35: 667-672.
61. Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4: 2115-2129.
62. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med 2008; 18: 151-157.
63. Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA 1979; 241: 1690-1691.
64. Nascimento B, Rizoli S, Rubenfeld G, et al. Cryoprecipitate transfusion: Assessing appropriateness and dosing in trauma. Transfus Med 2011; 21: 394-401.
65. Levi M, Ten Cate H. Disseminated intravascular coagulation. New Engl J Med 1999; 341: 586-592.
66. Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145: 24-33.
67. Pineo GF, Gallus AS, Hirsh J. Unexpected vitamin K deficiency in hospitalized patients. Can Med Assoc J 1973; 109: 880-883.
68. Alperin JB. Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. JAMA 1987; 258: 1916-1919.
69. Qu L, Kiss JE, Dargo G, et al. Outcomes of previously healthy pediatric patients with fulminant sepsis-induced multisystem organ failure receiving therapeutic plasma exchange. J Clin Apheresis 2011; 26: 208-213.
70. Stegmayr BG, Banga R, Berggren L, et al. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003; 31: 1730-1736.
71. Patel R, Cook DJ, Meade MO, et al. Burden of illness in venous thromboembolism in critical care: A multicenter observational study. J Crit Care 2005; 20: 341-347.
72. Marti-Carvajal AJ, Sola I, Lathyris D, et al. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011: CD004388.
73. Mullard A. Drug withdrawal sends critical care specialists back to basics. Lancet 2011; 378: 1769.
74. Heron M. Leading causes for 2007. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics; 2011.
75. Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury 2007; 38: 1336-1345.
76. Simmons JW, White CE, Ritchie JD, et al. Mechanism of injury affects acute coagulopathy of trauma in combat casualties. J Trauma 2011; 71: S74-S77.
77. Floccard B, Rugeri L, Faure A, et al. Early coagulopathy in trauma patients: An on-scene and hospital admission study. Injury 2012; 43: 26-32.
78. O'Keeffe T, Refaai M, Tchorz K, et al. A massive transfusion protocol to decrease blood component use and costs. Arch Surg 2008; 143: 686-690; discussion 690-681.
79. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248: 447-458.
80. Gunter OLJr, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: Identifying blood product ratios associated with improved survival. J Trauma 2008; 65: 527-534.
81. Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: Is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma 2008; 65: 261-270; discussion 270-261.
82. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096-1101, e1091-e1092.
83. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
84. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-298.
85. Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma 2007; 62: 564-569.
86. Afshari A, Wikkelso A, Brok J, et al. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011: CD007871.